Why Indivior’s Delaware redomiciliation matters more than a corporate address change
Find out how Indivior’s move to the United States reshapes governance, regulation, and investor perception in addiction treatment biotech.
Why BioCryst’s Astria acquisition reshapes long-acting competition in hereditary angioedema prophylaxis
BioCryst completes its Astria acquisition to expand long-acting hereditary angioedema leadership. Find out what this means for HAE treatment competition.
How urcosimod’s FDA compassionate use authorization reshapes development risk in ocular neuropathic pain
FDA allows compassionate use of urcosimod for neuropathic corneal pain. Read how this decision reshapes regulatory, clinical, and development risk.
Brazil rollout puts Bavarian Nordic’s chikungunya vaccine under regulatory and execution scrutiny
Find out how Bavarian Nordic’s Brazil rollout with Eurofarma puts its chikungunya vaccine to the ultimate regulatory and execution test.
Vaxcyte advances VAX-31 as Phase 3 trial design choices highlight regulatory and adoption priorities
Vaxcyte advances VAX-31 into pivotal adult and infant studies. Find out how trial design choices shape regulatory and adoption outcomes.
How amlitelimab’s dosing flexibility could disrupt biologic treatment patterns in atopic dermatitis
Sanofi’s amlitelimab advances toward filing in atopic dermatitis. Explore how dosing flexibility, durability data, and regional results shape its outlook.
How PDS0101 patent coverage reshapes competitive risk in HPV16 positive head and neck cancer development
PDS Biotechnology strengthens PDS0101 patent protection as Phase 3 strategy evolves. Discover what this changes for immunotherapy competition.
Why 60 Degrees Pharmaceuticals is betting on Runway Health to reshape malaria prevention access
Discover how 60 Degrees Pharmaceuticals is using telehealth to expand ARAKODA access and what this shift means for malaria prevention strategy.
Lucid Diagnostics gains strategic VA partnership to deploy EsoGuard across veteran programs
Discover how Lucid Diagnostics is expanding EsoGuard adoption with a new U.S. Veterans Affairs contract for early cancer screening.
Adaptin Bio prepares Phase 1 glioblastoma trial following preclinical progress in brain cancer candidate
Find out how Adaptin Bio is preparing a Phase 1 glioblastoma trial and why its preclinical progress matters for brain cancer treatment innovation.